Areas covered: This review will discuss the adverse events of the pivotal trials ledding to the approval of second-line therapies for the treatment of not oncogene-addicted NSCLC patients. Expert opinion: In recent years, new second-line options for NSCLC are: the anti-EGFR, afatinib (only in...
Cite this: Advances in Treatment Options for Early-Stage NSCLC - Medscape - Sep 07, 2022.Recommendations Why Lung Cancer Screening Is Not for Everyone news Europe Recommends Lung Cancer Drug Hetronifly news The Link Between Neurology and Oncology: LEMS and the Risk of SCLC 0.5 CME / ABIM...
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them. January 22nd 2025 My New Year’s Resolution After A Testicular Can...
The safety of second-line treatment options for non-small cell lung cancer Non-small-cell lung cancer (NSCLC) patients after first-line therapy ultimately suffer progression. At this time, many patients still have a good performan... A Rossi,P Maione,G Santabarbara,... - 《Expert Opinion ...
Some of the other drugs like amivantamab have clear EGFR and MET toxicities that are not ideal for certain patients. Having certain options to choose first or sequence if [a patient is] intolerable will be an important option,” Yu said. When clinicians do not have a biomarker to determine...
Treatment options for hearing loss are mostly based on medical devices, including hearing aids and cochlear implants; there are no pharmacological therapeutics currently in widespread use. Hair cells in the inner ear are the sensory cells for the detection of sound; hair cells are frequently affected...
Take it one day at a time and follow these wise tips when taking care of someone with advanced lung cancer. It's important to reach out for support, too.Explore More Video Traveling With NSCLC With lung cancer, you have to be aware of blood clots and decreased oxygen levels. Here’s ...
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of adv
Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use... Giovenzio,Genestreti,Francesco,... - 《Future Oncology》 被引量: 33发表: 2014年 First- and second-line treatment of advanced metastati...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available t